BTG (BTG) Given “Hold” Rating at Deutsche Bank

Deutsche Bank reaffirmed their hold rating on shares of BTG (LON:BTG) in a report published on Monday. Deutsche Bank currently has a GBX 645 ($8.40) price target on the stock.

Several other equities research analysts also recently weighed in on BTG. Peel Hunt cut their price target on BTG from GBX 700 ($9.12) to GBX 640 ($8.34) and set a hold rating on the stock in a research report on Thursday, May 24th. Numis Securities reissued a buy rating and set a GBX 840 ($10.94) target price on shares of BTG in a research note on Tuesday, June 5th. Shore Capital reissued a buy rating on shares of BTG in a research note on Friday, June 15th. Finally, Royal Bank of Canada reissued an underperform rating and set a GBX 510 ($6.64) target price on shares of BTG in a research note on Wednesday, June 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of GBX 697.50 ($9.09).

Shares of BTG opened at GBX 553.50 ($7.21) on Monday. BTG has a fifty-two week low of GBX 559.82 ($7.29) and a fifty-two week high of GBX 784 ($10.21).

In other news, insider Dame Pamela Louise Makin sold 73,410 shares of the stock in a transaction dated Tuesday, July 17th. The shares were sold at an average price of GBX 488 ($6.36), for a total transaction of £358,240.80 ($466,641.66). Also, insider Anne Thorburn bought 15,000 shares of the stock in a transaction dated Monday, July 23rd. The shares were purchased at an average cost of GBX 500 ($6.51) per share, for a total transaction of £75,000 ($97,694.41).

BTG Company Profile

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.

Further Reading: Asset Allocation

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with's FREE daily email newsletter.

Leave a Reply